Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST/A151216) (CIRB)
Researchers in this study are seeking patients for clinical trials assessing new treatments for non-small cell lung cancers that contain ALK and EGFR mutations. There are new drugs available and investigational drugs being assessed for these cancers when given after surgery.
Patients who have non-small cell lung cancer that has been or will be removed by surgery will be able to have their tumors screened for these mutations. If they have one of the mutations, they may participate in a clinical trial of a new therapy. If they don't have one of the mutations, their health will be monitored for up to five years.
Investigators want to learn more about lung cancer and why some treatments help some patients but stop working in others.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have confirmed or suspected stage IB, II, or IIIA operable non-small cell lung cancer.
- Patients may not have had chemotherapy or radiation therapy before surgery, nor prior treatments with drugs targeting ALK or EGFR.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. David R. Jones at 212-639-6428.